

## Review Article

# Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

Paola Dongiovanni,<sup>1</sup> Stefano Romeo,<sup>2,3</sup> and Luca Valenti<sup>1,4</sup>

<sup>1</sup>Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy

<sup>2</sup>Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at the University of Gothenburg, Medicinaregatan 3, 40530 Gothenburg, Sweden

<sup>3</sup>Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Viale Europa, 88100 Catanzaro, Italy

<sup>4</sup>Department of Pathophysiology and Transplantation, University of Milan, Via Francesco Sforza 35, 20122 Milan, Italy

Correspondence should be addressed to Luca Valenti; [luca.valenti@unimi.it](mailto:luca.valenti@unimi.it)

Received 14 October 2014; Accepted 18 December 2014

Academic Editor: Shira Zelber-Sagi

Copyright © 2015 Paola Dongiovanni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Liver fat accumulation generally related to systemic insulin resistance characterizes nonalcoholic fatty liver disease (NAFLD), which in the presence of nonalcoholic steatohepatitis (NASH) can progress towards cirrhosis and hepatocellular carcinoma. Due to the epidemic of obesity, NAFLD is now the most frequent liver disease in Western countries. Epidemiological, familial, and twin studies provide evidence for a strong genetic component of NAFLD susceptibility. Recently, genome-wide association studies led to the identification of the major inherited determinants of hepatic fat accumulation: *patatin-like phospholipase domain-containing 3 (PNPLA3)* I148M gene and *transmembrane 6 superfamily member 2 (TM6SF2)* E167K gene variants, involved in lipid droplets remodelling and very low-density lipoproteins secretion, are the major determinants of interindividual differences in liver steatosis, and susceptibility to progressive NASH. In this review, we aimed to provide an overview of recent insights into the genetics of hepatic fat accumulation and steatohepatitis.

## 1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is defined by liver fat deposition in the absence of excessive alcohol intake. NAFLD is frequently present in obese individuals and it is also related to metabolic changes such as systemic insulin resistance [1]. In susceptible individuals, hepatic steatosis may result in oxidative hepatocellular damage, inflammation, and activation of fibrogenesis, namely, nonalcoholic steatohepatitis (NASH) [2]. This condition potentially progresses towards liver cirrhosis and hepatocellular carcinoma [3]. Due to the epidemic of obesity and the advances in the prevention and treatment of viral hepatitis NAFLD is now the most frequent liver disease and the leading cause of altered liver enzymes in Western countries [4, 5]. Subsequently, NASH

will become the leading cause of end-stage liver disease, liver transplantation, and hepatocellular carcinoma within the next decades.

Epidemiological, familial, and twin studies provide evidence for heritability of hepatic fat content, NAFLD, and *bona fide* metabolic cirrhosis [6, 7]. In the last years, the genetic determinants of steatosis are being unveiled using genome-wide association studies. These studies have identified *patatin-like phospholipase domain-containing 3 (PNPLA3)* gene variant, involved in hepatocellular lipid droplets remodelling and very low-density lipoprotein (VLDL) secretion, as a major determinant of interindividual and ethnicity-related differences in hepatic fat content [8, 9]. The *transmembrane 6 superfamily member 2 (TM6SF2)* E167K gene variant, interfering with VLDL secretion, which may be stimulated in early

NAFLD [10], has recently been shown to increase susceptibility to progressive NASH by compartmentalization of lipids within hepatocytes [11, 12]. Furthermore, case-control studies demonstrated a role of other genetic variants implicated in inflammation [13], insulin signaling [14], oxidative stress, iron metabolism [15–18], and fibrogenesis [19] in the progression of fatty liver towards NASH associated fibrosis.

Newly identified genetic risk variants could provide a useful tool for the clinical management and prognosis of patients with NAFLD. They may also lead to the identification of drugs for treating NASH, a condition for which specific pharmacological treatment is still lacking.

The main purpose of this narrative review is to provide an overview of recent insights into the genetics of hepatic fat accumulation and steatohepatitis, specifically focusing on inherited variants regulating lipid metabolism. These recent advances have contributed in a short time to unravel the pathogenesis of NAFLD and may soon translate into therapeutic advances. For a comprehensive overview of all studies related to NAFLD and NASH genetics see the recent review by our group [20].

## 2. Pathophysiology of NAFLD and NASH: The Current View

The acronym NAFLD defines a wide spectrum of liver disease characterized by hepatic fat accumulation in the form of triglycerides exceeding 5% of liver mass in the absence of significant alcohol consumption. NAFLD may remain uncomplicated or progress into severe hepatitis characterized by severe steatosis, lobular inflammation, and hepatocellular damage and apoptosis with activation of fibrogenesis [21]. The final outcome of NAFLD is life threatening conditions, namely, cirrhosis and hepatocellular carcinoma [3]. Hepatic fat accumulation results from an unbalance between triglycerides acquisition, synthesis, utilization, and secretion [22, 23] and it represents the safest way to store fatty acids (FFAs) in the liver [24]. Several lines of evidence support a model where the excess in hepatocellular triglycerides derives from increased peripheral lipolysis [25] due to adipose tissue insulin resistance [26], an increased hepatic lipogenesis due to hyperinsulinemia, and an excessive food intake (Figure 1(a)). Indeed, the major determinant of NAFLD is systemic insulin resistance [1, 27]. Steatosis *per se* may then in turn worsen hepatic insulin resistance contributing to metabolic disturbances and cardiovascular damage [28, 29]. Reduction in hepatocellular triglycerides secretion through VLDL [23] and in utilization due to mitochondrial damage is also involved in hepatic fat accumulation.

The development of NASH has been classically ascribed to the occurrence of multiple parallel “second-hits,” leading to the activation of inflammation, in the context of hepatic steatosis [30, 31]. This second insult may be related to a variety of conditions: (a) direct hepatic lipotoxicity, (b) hepatocellular oxidative stress secondary to free radicals produced during  $\beta$ - and omega-oxidation of FFAs, (c) inflammation triggered by endotoxin engaging Toll-like receptor-4 in Kupffer cells and hepatocytes due to increased intestinal

permeability, (d) qualitative and quantitative changes in gut microbiota [32–34], (e) release of cytokines by the hepatic stellate cells, and (f) endoplasmic reticulum stress. All these conditions lead in the end to inflammation, cellular damage, and activation of fibrogenesis in the liver [35].

## 3. Heritability of NAFLD and NASH

Epidemiological, familial, and twin studies [6, 7] and clinical case series showing familial clustering support a strong heritability component in NAFLD and NASH [36]. Twin studies show that ALT levels, mostly reflecting liver fat content in the absence of alcohol abuse or viral hepatitis, are a heritable trait explained up to 60% by genetic factors [37]. A study population among Danish twins identified substantial heritability (35–61%) for levels of aminotransferases [38].

Ethnic differences have been reported in the prevalence of NAFLD and NASH [4, 39]. Hispanics are at higher risk than individuals of European descent, whereas those from African descent are protected from these conditions irrespective of diabetes and excess body weight [7, 40].

## 4. PNPLA3 I148M Mutation Is the Major Genetic Determinant of NAFLD and NASH

The major determinant of the interindividual and ethnicity-related differences in hepatic fat content was identified by an exome wide association study. This is the rs738409 C>G single nucleotide polymorphism (SNP) in the *PNPLA3* gene, encoding for the isoleucine to methionine substitution at position 148 (I148M) [8]. In humans *PNPLA3*, also called *adiponutrin*, encodes a 481 amino acid membrane protein localized in the endoplasmic reticulum and at the surface of lipid droplets. In human this protein has the highest expression in hepatic stellate cells, retina, and hepatocytes. In mice *Pnpla3* is upregulated in the liver after feeding and during insulin resistance by fatty acids and the master regulator of lipogenesis SREBP-1c [41]. Although the mechanism underlying the progression to liver disease remains an area of active research, *PNPLA3* has a triglyceride and retinyl-palmitate esterase activity [42–44]. The isoleucine to methionine substitution leads to a loss of function of these activities, of the enzyme, leading to changes in an impairment of lipid catabolism, lipid droplets remodelling, and VLDL secretions [42, 45, 46]. This would favour hepatocellular accumulation of triglycerides during insulin resistance (Figure 1(b)).

A robust association of the I148M variant with hepatic fat content has been confirmed in several studies both in adults [8, 47–58] and in developmental age [59–62]. Most importantly, in carriers of the I148M mutant protein environmental stressors, namely, obesity [63], abdominal fat [64, 65], excessive alcohol consumption [66], chronic viral hepatitis [67, 68], or iron overload [69], trigger progressive liver damage [58]. Dietary habits are also relevant; indeed, the magnitude of the increase in liver enzymes in I148M carriers is correlated to high dietary carbohydrate and sugar consumption [70–72] and increased omega6/omega3 polyunsaturated fatty acids ratio [73, 74]. Interestingly, the carriers of the *PNPLA3* I148M




FIGURE 1: Molecular genetics of NASH. (a) NAFLD is characterized by the hepatic fat accumulation in lipid droplets resulting from an unbalance between triglycerides acquisition and secretion. FFA stored as triglycerides during hepatic steatosis derive from peripheral lipolysis related to adipose tissue insulin resistance, followed by *de novo* lipogenesis induced by hyperinsulinemia, and excessive food intake. In the liver, FFA can be catabolized through  $\beta$ -oxidation and reesterification to triglycerides and stored as lipid droplets or exported as VLDL. (b) *PNPLA3* I148M variant is attached on the surface of lipid droplets reducing triglyceride breakdown leading to lipid retention in the hepatocyte lipid droplet. (c) *TM6SF2* E167K variant reduces triglycerides secretion through VLDL, leading to hepatocellular retention of lipids.

variant have a substantial increased risk in cirrhosis and hepatocellular carcinoma [66, 67, 75–84] independently of the predisposition to steatosis. This suggests that PNPLA3 contributes directly to the fibrogenesis and carcinogenesis [9, 57, 61, 83, 85]. Indeed, PNPLA3 retinyl-palmitate activity in hepatic stellate cells may influence hepatic regeneration and differentiation by altering availability of retinol, potent regulators of these phenomena [44].

To summarize the PNPLA3 I148M variant is a robust genetic determinant of hepatic steatosis triggered by a number of environmental factors [9, 85] and the PNPLA3 associated steatohepatitis (PASH) may be mediated by a direct effect on hepatocyte and on hepatic stellate cells [86]. The mechanisms linking the I148M PNPLA3 variant with liver disease progression and hepatocellular carcinoma development have recently been reviewed by our group [9, 83].

### 5. *TM6SF2* E167K and Very Low-Density Lipoproteins Secretion

In 2014, two exome and genome wide association studies were reported identifying the rs58542926 C > T genetic variant of the *transmembrane 6 superfamily member 2* gene (*TM6SF2*), which encodes the loss-of-function lysine (E) to glutamic acid (K) at position 167 substitution (E167K), as a determinant of hepatic triglyceride content, serum aminotransferases, and lower serum lipoproteins [11, 87]. The same studies demonstrated that silencing of *TM6SF2* reduces secretion of VLDL resulting in intrahepatic retention of triglycerides and steatosis in mice and in hepatocytes *in vitro* [11, 87, 88].

Very recently, in large collaborative European study evaluating a large cross-sectional cohort of 1,201 individuals at risk of NASH it was demonstrated that the E167K variant is associated with the full spectrum of liver damage associated with hepatic fat accumulation, including NASH, hepatocellular ballooning, and necroinflammation. Importantly, the association between the E167K variant and advanced fibrosis was abolished after conditioning for NASH, suggesting that fibrosis progression is mediated by the effect of the genetic variant on intracellular retention of lipids, mainly triglycerides and cholesterol, within hepatocytes. In keeping with this interpretation, the severity of liver damage was found to be correlated with the amount of hepatic triglycerides accumulation in patients with NAFLD [89].

The link between the *NCAN* locus and NAFLD severity [90, 91] and an independent study reporting an association between *TM6SF2* and moderate/severe fibrosis [92] support the association between *TM6SF2* and liver damage in NAFLD. Indeed, the E167K is the causal variant explaining the association of the *NCAN* locus with altered lipid metabolism [11, 87].

The association of E167K with NASH and advanced fibrosis contradicts the notion that long-term storage of fatty acids in hepatocytes in triglycerides is benign [93]. In addition, it has been demonstrated that also the PNPLA3 I148M variant by altering lipid droplets remodelling impairs the ability to export triglycerides to secreted VLDL [45,

46]. The deleterious effect on liver damage of the impaired ability to secrete triglycerides in VLDL is also supported by the association between progressive liver disease and rare *apolipoprotein B (APOB)* and *microsomal triglyceride transfer protein (MTTP)* mutations directly causing VLDL retention [93, 94]. A possible alternative mechanism may be related to the toxicity of excessive hepatocellular cholesterol and the consequent mitochondrial damage in carriers of the E167K variant [95, 96]. All in all, these novel findings suggest that compartmentalization of neutral lipids within hepatocytes is harmful for the liver.

### 6. *GCKR* and Lipogenesis

In a meta-analysis of combined GWAS datasets, besides PNPLA3 I148M, other genetic loci were associated with liver fat content. These included *NCAN* (explained by *TM6SF2*, as mentioned previously), *glucokinase regulator (GCKR)*, SNP rs780094), and *lysophospholipase-like 1 (LYPLAL1)*, SNP rs12137855). Both variants in *GCKR*, a regulator of glucose metabolism and *LYPLAL1*, involved in triglycerides catabolism, were also shown to influence liver damage [97, 98]. It has been hypothesized that the association of the rs780094 *GCKR* polymorphism with hepatic fat accumulation can be explained by the linkage disequilibrium with rs1260326, encoding for the P446L protein variant. The P446L variant indeed affects *GCKR* ability to negatively regulate glucokinase in response to fructose-6-phosphate, thereby determining constitutive activation of hepatic glucose uptake [99]. This would lead to decreased circulating fasting glucose and insulin levels, but on the other hand it would lead to increased glycolysis and production of malonyl-CoA. Malonyl-CoA is a key metabolite, because it favors hepatic fat accumulation by serving as a substrate for lipogenesis and blocks fatty acid oxidation through the inhibition of carnitine-palmitoyl transferase-1. The combined effects of PNPLA3 I148M and *GCKR* P446L polymorphisms explained up to one-third of variability in liver fat content in a recently reported series of obese children [100, 101]. All this body of evidence shows that genetic variants influencing hepatocellular lipid accumulation predispose both to fatty liver and to progressive NASH.

### 7. Other Variants Regulating Lipid Metabolism

According to the aforementioned hypothesis, other genes involved in hepatic fat uptake, synthesis, storage, and mobilization are therefore candidates to influence the development and progression of NAFLD. Among these are variants in peroxisome proliferator-activated nuclear receptors (PPAR). PPAR $\alpha$ , a molecular target of long chain fatty acids, eicosanoids, and fibrates [102], is highly expressed in tissues that catabolize fatty acids such as the liver, where, under condition of increased hepatic fatty acid influx or decreased fatty acid efflux, PPAR $\alpha$  activation prevents the accumulation of triglycerides by increasing the rate of fatty acid catabolism. However, the Leu162Val loss-of-function PPAR $\alpha$  variant did

not influence the risk of NAFLD and the severity of liver disease [103, 104].

PPAR $\gamma$  is highly expressed in adipose tissue and regulates adipocyte differentiation, FFA uptake, and storage. Pharmacological activation of PPAR $\gamma$  improves insulin resistance in diabetes and decreases steatosis in NAFLD patients by restoring adipose tissue insulin sensitivity and adiponectin release [105, 106]. The Pro12Ala loss-of-function SNP in *PPAR $\gamma$ 2*, inducing a modest impairment of transcriptional activity due to decreased DNA-binding affinity, was associated with a reduction of PPAR $\gamma$  activity in adipose tissue as well as decreased insulin resistance [107]. However, inconsistent results have been reported concerning the association of this variant with the severity of liver damage in NAFLD [103, 104].

Another interesting candidate is represented by *Lipin1* (*LPIN1*), a phosphatidate phosphatase that is highly expressed in the liver and adipose tissue, and is involved in the synthesis of phospholipids downstream of the step catalysed by PNPLA3 [108] and of triglycerides. *LPIN1* is required for adipogenesis and the normal metabolic flux between adipose tissue and liver, where it also acts as an inducible transcriptional coactivator to regulate fatty acid metabolism [56]. *LPIN1* variants have been associated with several components of the metabolic syndrome, including body mass, insulin levels, resting metabolic rate, and responsiveness to insulin sensitizers [109, 110]. In a pediatric population, *LPIN1* rs13412852 TT genotype was protective towards NAFLD [111]. Although independent validation of these results is required, these data suggest that *LPIN1* variants predispose to progressive NASH at early age by influencing lipogenesis and lipid metabolism.

Fatty acid transport proteins (FATP) hold a crucial role in mediating cellular FFA uptake. In the liver FATP2 and FATP5 are predominantly expressed [112]. *FATP5* encodes a multifunctional protein which increases the hepatic FFA uptake and activates very long-chain fatty acids and has bile-CoA ligase activity [113, 114]. *FATP5* silencing reversed diet-induced NAFLD and improved hyperglycemia in mice [115]. Interestingly, the rs56225452 *FATP5* promoter variant linked to transcriptional activity has been associated with ALT levels in a population study and with steatosis severity in NAFLD patients [116].

Interestingly, a genetic variant in the promoter region regulating the expression of uncoupling protein 2 (*UCP2*) has recently been associated with altered lipoprotein metabolism and reduced susceptibility to NASH [117]. Besides regulating mitochondrial redox status and energy dissipation, *UCP2* is involved in the export of fatty acids from mitochondria in hepatocytes and is induced during steatosis. It is therefore possible that it may modulate the risk of NASH by altering mitochondrial fluxes of lipids during NAFLD.

Apolipoprotein C3 (*APOC3*) is a major constituent of VLDL, chylomicrons, and HDL cholesterol, which inhibits lipoprotein lipase and triglyceride clearance [118]. Petersen et al. reported that two common *APOC3* T-455C and C-482T promoter variants predispose to liver fat accumulation in Indian individuals. However, these data have not been confirmed in large population studies and in other ethnic groups. Furthermore, *APOC3* variants were not associated

with the histological severity of liver damage in NAFLD [119–121]. These data suggest that genetic factors influencing triglyceride metabolism outside the liver are not involved in the pathogenesis of progressive NAFLD.

## 8. Other Variants Not Implicated in Lipid Metabolism

Although recent genetic evidence concordantly points to a major role of variants influencing intrahepatocellular lipid metabolism in the pathogenesis of NAFLD and progressive NASH, as recently reviewed by our group [20], other genetic variants may be implicated in the progression of liver disease.

The most solid associations have been collected for genetic variants involved in the regulation of inflammation, such as *TNFA* and *IL28B* polymorphisms [13, 122], oxidative stress [13, 122], iron metabolism [15, 17, 18], which is frequently altered in NAFLD [124], and fibrogenesis [19]. However, the overall evidence supporting these associations is weaker than that already obtained for the *PNPLA3* I148M and *TM6SF2* E167K genetic variants, as these results still need independent validation in independent cohorts.

## 9. Conclusions

Genes play a key role in the susceptibility and progression of NAFLD. To date, the *PNPLA3* I148M and *TM6SF2* E167K gene variants are the major determinants of interindividual differences in liver steatosis and susceptibility to progressive NASH. Both of these genes determine liver fat retention through lipid droplets and very low-density lipoproteins modifications. *PNPLA3* affects also directly hepatic stellate cells and retinol metabolism. These novel findings suggest that hepatocellular accumulation of neutral lipids is harmful for the liver. Several other genetic variants, including rare mutations, involved in the regulation of hepatocellular lipid metabolism, are being scrutinized.

Future challenges will be (a) to understand the molecular mechanisms underlying the association between gene variants and progressive liver disease, (b) to evaluate the impact of gene variants in the clinical practice to stratify individual risk, and (c) to examine pharmacogenetic response to available therapies. This knowledge will offer insights into pathogenesis of NASH and importantly suggest novel therapeutic targets.

## Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

## Acknowledgment

Paola Dongiovanni was financed by Italian fiscal contribution 5X1000-2010 devolved to Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico.

## References

- [1] G. Marchesini, M. Brizi, G. Bianchi et al., "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome," *Diabetes*, vol. 50, no. 8, pp. 1844–1850, 2001.
- [2] C. P. Day, "From fat to inflammation," *Gastroenterology*, vol. 130, no. 1, pp. 207–210, 2006.
- [3] E. Bugianesi, N. Leone, E. Vanni et al., "Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma," *Gastroenterology*, vol. 123, no. 1, pp. 134–140, 2002.
- [4] J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity," *Hepatology*, vol. 40, no. 6, pp. 1387–1395, 2004.
- [5] S. Bellentani, G. Saccoccio, F. Masutti et al., "Prevalence of and risk factors for hepatic steatosis in northern Italy," *Annals of Internal Medicine*, vol. 132, no. 2, pp. 112–117, 2000.
- [6] J. B. Schwimmer, M. A. Celedon, J. E. Lavine et al., "Heritability of nonalcoholic fatty liver disease," *Gastroenterology*, vol. 136, no. 5, pp. 1585–1592, 2009.
- [7] R. Guerrero, G. L. Vega, S. M. Grundy, and J. D. Browning, "Ethnic differences in hepatic steatosis: an insulin resistance paradox?" *Hepatology*, vol. 49, no. 3, pp. 791–801, 2009.
- [8] S. Romeo, J. Kozlitina, C. Xing et al., "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease," *Nature Genetics*, vol. 40, no. 12, pp. 1461–1465, 2008.
- [9] P. Dongiovanni, B. Donati, R. Fares et al., "PNPLA3 I148M polymorphism and progressive liver disease," *World Journal of Gastroenterology*, vol. 19, no. 41, pp. 6969–6978, 2013.
- [10] S. Zelber-Sagi, F. Salomone, H. Yeshua et al., "Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease," *Liver International*, vol. 34, no. 6, pp. e128–e135, 2014.
- [11] J. Kozlitina, E. Smagris, S. Stender et al., "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease," *Nature Genetics*, vol. 46, no. 4, pp. 352–356, 2014.
- [12] P. Dongiovanni, S. Petta, C. Maglio et al., "TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease," *Hepatology*, 2014.
- [13] L. Valenti, A. L. Fracanzani, P. Dongiovanni et al., "Tumor necrosis factor  $\alpha$  promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease," *Gastroenterology*, vol. 122, no. 2, pp. 274–280, 2002.
- [14] P. Dongiovanni, L. Valenti, R. Rametta et al., "Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease," *Gut*, vol. 59, no. 2, pp. 267–273, 2010.
- [15] L. Valenti, E. Canavesi, E. Galmozzi et al., "Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease," *Journal of Hepatology*, vol. 53, no. 5, pp. 927–933, 2010.
- [16] A. Al-Serri, Q. M. Anstee, L. Valenti et al., "The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies," *Journal of Hepatology*, vol. 56, no. 2, pp. 448–454, 2012.
- [17] L. Valenti, R. Rametta, P. Dongiovanni et al., "The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease," *PLoS ONE*, vol. 7, no. 11, Article ID e48804, 2012.
- [18] L. Valenti, A. L. Fracanzani, E. Bugianesi et al., "HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease," *Gastroenterology*, vol. 138, no. 3, pp. 905–912, 2010.
- [19] L. Miele, G. Beale, G. Patman et al., "The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease," *Gastroenterology*, vol. 135, no. 1, pp. 282–291, 2008.
- [20] P. Dongiovanni, Q. M. Anstee, and L. Valenti, "Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment," *Current Pharmaceutical Design*, vol. 19, no. 29, pp. 5219–5238, 2013.
- [21] D. E. Kleiner, E. M. Brunt, M. van Natta et al., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease," *Hepatology*, vol. 41, no. 6, pp. 1313–1321, 2005.
- [22] J. C. Cohen, J. D. Horton, and H. H. Hobbs, "Human fatty liver disease: old questions and new insights," *Science*, vol. 332, no. 6037, pp. 1519–1523, 2011.
- [23] E. Fabbrini, B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson, and S. Klein, "Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease," *Gastroenterology*, vol. 134, no. 2, pp. 424–431, 2008.
- [24] K. Yamaguchi, L. Yang, S. McCall et al., "Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis," *Hepatology*, vol. 45, no. 6, pp. 1366–1374, 2007.
- [25] K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease," *Journal of Clinical Investigation*, vol. 115, no. 5, pp. 1343–1351, 2005.
- [26] E. Bugianesi, A. Gastaldelli, E. Vanni et al., "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms," *Diabetologia*, vol. 48, no. 4, pp. 634–642, 2005.
- [27] G. Marchesini, M. Brizi, A. M. Morselli-Labate et al., "Association of nonalcoholic fatty liver disease with insulin resistance," *The American Journal of Medicine*, vol. 107, no. 5, pp. 450–455, 1999.
- [28] K. M. Korenblat, E. Fabbrini, B. S. Mohammed, and S. Klein, "Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects," *Gastroenterology*, vol. 134, no. 5, pp. 1369–1375, 2008.
- [29] G. Targher, C. P. Day, and E. Bonora, "Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease," *The New England Journal of Medicine*, vol. 363, no. 14, pp. 1341–1350, 2010.
- [30] C. P. Day and O. F. W. James, "Steatohepatitis: a tale of two 'Hits'?" *Gastroenterology*, vol. 114, no. 4, pp. 842–845, 1998.
- [31] H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis," *Hepatology*, vol. 52, no. 5, pp. 1836–1846, 2010.
- [32] L. Valenti, A. L. Fracanzani, and S. Fargion, "The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?" *Seminars in Immunopathology*, vol. 31, no. 3, pp. 359–369, 2009.

- [33] L. Miele, V. Valenza, G. la Torre et al., "Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease," *Hepatology*, vol. 49, no. 6, pp. 1877–1887, 2009.
- [34] M. T. Bardella, L. Valenti, C. Pagliari et al., "Searching for coeliac disease in patients with non-alcoholic fatty liver disease," *Digestive and Liver Disease*, vol. 36, no. 5, pp. 333–336, 2004.
- [35] Q. M. Anstee, A. K. Daly, and C. P. Day, "Genetics of alcoholic and nonalcoholic fatty liver disease," *Seminars in Liver Disease*, vol. 31, no. 2, pp. 128–146, 2011.
- [36] I. R. Willner, B. Waters, S. R. Patil, A. Reuben, J. Morelli, and C. A. Riely, "Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease," *The American Journal of Gastroenterology*, vol. 96, no. 10, pp. 2957–2961, 2001.
- [37] J. Makkonen, K. H. Pietiläinen, A. Rissanen, J. Kaprio, and H. Yki-Järvinen, "Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins," *Journal of Hepatology*, vol. 50, no. 5, pp. 1035–1042, 2009.
- [38] T. Takehara, T. Tatsumi, T. Suzuki et al., "Hepatocyte-specific disruption of Bcl-x L leads to continuous hepatocyte apoptosis and liver fibrotic responses," *Gastroenterology*, vol. 127, no. 4, pp. 1189–1197, 2004.
- [39] Y. Minamiyama, S. Takemura, S. Kodai et al., "Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats," *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 298, no. 6, pp. E1140–E1149, 2010.
- [40] R. Kirsch, H. P. Sijtsma, M. Tlali, A. D. Marais, and P. D. L. M. Hall, "Effects of iron overload in a rat nutritional model of non-alcoholic fatty liver disease," *Liver International*, vol. 26, no. 10, pp. 1258–1267, 2006.
- [41] Y. Huang, S. He, J. Z. Li et al., "A feed-forward loop amplifies nutritional regulation of PNPLA3," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 17, pp. 7892–7897, 2010.
- [42] S. He, C. McPhaul, J. Z. Li et al., "A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis," *The Journal of Biological Chemistry*, vol. 285, no. 9, pp. 6706–6715, 2010.
- [43] P. Pingitore, C. Pirazzi, R. M. Mancina et al., "Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function," *Biochimica et Biophysica Acta (BBA)—Molecular and Cell Biology of Lipids*, vol. 1841, no. 4, pp. 574–580, 2014.
- [44] C. Pirazzi, L. Valenti, B. M. Motta et al., "PNPLA3 has retinylpalmitate lipase activity in human hepatic stellate cells," *Human Molecular Genetics*, vol. 23, no. 15, pp. 4077–4085, 2014.
- [45] C. Pirazzi, M. Adiels, M. A. Burza et al., "Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro," *Journal of Hepatology*, vol. 57, pp. 1257–1262, 2012.
- [46] H. Ruhanen, J. D. Perttilä, M. D. Hölttä-Vuori et al., "PNPLA3 mediates hepatocyte triacylglycerol remodeling," *Journal of Lipid Research*, vol. 55, no. 4, pp. 739–746, 2014.
- [47] X. Yuan, D. Waterworth, J. R. B. Perry et al., "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes," *American Journal of Human Genetics*, vol. 83, no. 4, pp. 520–528, 2008.
- [48] L. E. Johansson, U. Lindblad, C. A. Larsson, L. Råstam, and M. Ridderstråle, "Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity," *European Journal of Endocrinology*, vol. 159, no. 5, pp. 577–583, 2008.
- [49] A. Kotronen, L. E. Johansson, L. M. Johansson et al., "A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans," *Diabetologia*, vol. 52, no. 6, pp. 1056–1060, 2009.
- [50] A. Kotronen, M. Peltonen, A. Hakkarainen et al., "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors," *Gastroenterology*, vol. 137, no. 3, pp. 865–872, 2009.
- [51] B. Kollerits, S. Coassin, N. D. Beckmann et al., "Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins," *Human Molecular Genetics*, vol. 18, no. 23, pp. 4669–4676, 2009.
- [52] S. Sookoian, G. O. Castaño, A. L. Burgueño, T. F. Gianotti, M. S. Rosselli, and C. J. Pirola, "A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity," *The Journal of Lipid Research*, vol. 50, no. 10, pp. 2111–2116, 2009.
- [53] K. Kantartzis, A. Peter, F. Machicao et al., "Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene," *Diabetes*, vol. 58, no. 11, pp. 2616–2623, 2009.
- [54] S. Romeo, F. Sentinelli, S. Dash et al., "Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent," *International Journal of Obesity*, vol. 34, no. 1, pp. 190–194, 2010.
- [55] Y. Rotman, C. Koh, J. M. Zmuda, D. E. Kleiner, and T. J. Liang, "The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease," *Hepatology*, vol. 52, no. 3, pp. 894–903, 2010.
- [56] E. K. Speliotes, J. L. Butler, C. D. Palmer, B. F. Voight, and J. N. Hirschhorn, "PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease," *Hepatology*, vol. 52, no. 3, pp. 904–912, 2010.
- [57] L. Valenti, A. Al-Serri, A. K. Daly et al., "Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease," *Hepatology*, vol. 51, no. 4, pp. 1209–1217, 2010.
- [58] S. Sookoian and C. J. Pirola, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease," *Hepatology*, vol. 53, no. 6, pp. 1883–1894, 2011.
- [59] S. Romeo, F. Sentinelli, V. M. Cambuli et al., "The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life," *Journal of Hepatology*, vol. 53, no. 2, pp. 335–338, 2010.
- [60] N. Santoro, R. Kursawe, E. D'Adamo et al., "A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents," *Hepatology*, vol. 52, no. 4, pp. 1281–1290, 2010.
- [61] L. Valenti, A. Alisi, E. Galmozzi et al., "I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease," *Hepatology*, vol. 52, no. 4, pp. 1274–1280, 2010.

- [62] A. Viitasalo, J. Pihlajamaki, V. Lindi et al., "Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year follow-up in normal weight and overweight children: the PANIC study," *Pediatric Obesity*, 2014.
- [63] S. Romeo, F. Sentinelli, S. Dash et al., "Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent," *International Journal of Obesity*, vol. 34, no. 1, pp. 190–194, 2010.
- [64] E. Miraglia del Giudice, A. Grandone, G. Cirillo et al., "The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat," *PLoS ONE*, vol. 6, no. 11, Article ID e27933, 2011.
- [65] M. Graff, K. E. North, N. Franceschini et al., "PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI Family Heart Study," *International Journal of Obesity*, vol. 37, no. 3, pp. 432–438, 2013.
- [66] C. Tian, R. P. Stokowski, D. Kershenovich, D. G. Ballinger, and D. A. Hinds, "Variant in PNPLA3 is associated with alcoholic liver disease," *Nature Genetics*, vol. 42, no. 1, pp. 21–23, 2010.
- [67] L. Valenti, M. Rumi, E. Galmozzi et al., "Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C," *Hepatology*, vol. 53, no. 3, pp. 791–799, 2011.
- [68] M. Viganò, L. Valenti, P. Lampertico et al., "Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B," *Hepatology*, vol. 58, no. 4, pp. 1245–1252, 2013.
- [69] L. Valenti, P. Maggioni, A. Piperno et al., "Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis," *World Journal of Gastroenterology*, vol. 18, no. 22, pp. 2813–2820, 2012.
- [70] J. N. Davis, K.-A. Lê, R. W. Walker et al., "Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption," *The American Journal of Clinical Nutrition*, vol. 92, no. 6, pp. 1522–1527, 2010.
- [71] V. Nobili, D. Liccardo, G. Bedogni et al., "Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents," *Genes and Nutrition*, vol. 9, no. 3, 2014.
- [72] K. Sevastianova, A. Santos, A. Kotronen et al., "Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans," *American Journal of Clinical Nutrition*, vol. 96, no. 4, pp. 727–734, 2012.
- [73] N. Santoro, M. Savoye, G. Kim et al., "Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake," *PLoS ONE*, vol. 7, no. 5, Article ID e37827, 2012.
- [74] V. Nobili, G. Bedogni, B. Donati, A. Alisi, and L. Valenti, "The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-Alcoholic fatty liver disease," *Journal of Medicinal Food*, vol. 16, no. 10, pp. 957–960, 2013.
- [75] E. Trépo, P. Pradat, A. Potthoff et al., "Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C," *Hepatology*, vol. 54, no. 1, pp. 60–69, 2011.
- [76] L. Valenti, A. Aghemo, A. F. Stättermayer et al., "Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin," *Alimentary Pharmacology and Therapeutics*, vol. 35, no. 12, pp. 1434–1442, 2012.
- [77] L. Valenti, M. Colombo, and S. Fargion, "Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C," *Journal of Hepatology*, vol. 55, no. 6, pp. 1470–1471, 2011.
- [78] F. Stickel, S. Buch, K. Lau et al., "Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians," *Hepatology*, vol. 53, no. 1, pp. 86–95, 2011.
- [79] E. Falletti, C. Fabris, S. Cmet et al., "PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence," *Liver International*, vol. 31, no. 8, pp. 1137–1143, 2011.
- [80] E. Trepo, E. Guyot, N. Ganne-Carrie et al., "PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis," *Hepatology*, vol. 55, no. 4, pp. 1307–1308, 2012.
- [81] H. D. Nischalke, C. Berger, C. Luda et al., "The PNPLA3 rs738409 I48M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis," *PLoS ONE*, vol. 6, no. 11, Article ID e27087, 2011.
- [82] F. Stickel and J. Hampe, "Genetic determinants of alcoholic liver disease," *Gut*, vol. 61, no. 1, pp. 150–159, 2012.
- [83] L. Valenti, P. Dongiovanni, S. Ginanni Corradini, M. A. Burza, and S. Romeo, "PNPLA3 I148M variant and hepatocellular carcinoma: a common genetic variant for a rare disease," *Digestive and Liver Disease*, vol. 45, no. 8, pp. 619–624, 2013.
- [84] E. Trépo, P. Nahon, G. Bontempi et al., "Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data," *Hepatology*, vol. 59, no. 6, pp. 2170–2177, 2014.
- [85] L. Valenti, A. Alisi, and V. Nobili, "I148M PNPLA3 variant and progressive liver disease: a new paradigm in hepatology," *Hepatology*, vol. 56, no. 2, pp. 1883–1889, 2012.
- [86] M. Krawczyk, P. Portincasa, and F. Lammert, "PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease," *Seminars in Liver Disease*, vol. 33, no. 4, pp. 369–379, 2013.
- [87] O. L. Holmen, H. Zhang, Y. Fan et al., "Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk," *Nature Genetics*, vol. 46, no. 4, pp. 345–351, 2014.
- [88] H. Mahdessian, A. Taxiarchis, S. Popov et al., "TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 24, pp. 8913–8918, 2014.
- [89] N. Chalasani, L. Wilson, D. E. Kleiner, O. W. Cummings, E. M. Brunt, and A. Ünalp, "Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease," *Journal of Hepatology*, vol. 48, no. 5, pp. 829–834, 2008.
- [90] E. K. Seliotes, L. M. Yerges-Armstrong, J. Wu et al., "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits," *PLoS Genetics*, vol. 7, no. 3, Article ID e1001324, 2011.



- [91] A. Gorden, R. Yang, L. M. Yerges-Armstrong et al., "Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity," *Human Heredity*, vol. 75, no. 1, pp. 34–43, 2013.
- [92] Y.-L. Liu, H. L. Reeves, A. D. Burt et al., "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease," *Nature Communications*, vol. 5, article 4309, 2014.
- [93] A. B. Cefalu, J. P. Pirruccello, D. Noto et al., "A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 8, pp. 2021–2025, 2013.
- [94] M. Di Filippo, P. Moulin, P. Roy et al., "Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia," *Journal of Hepatology*, vol. 61, pp. 891–902, 2014.
- [95] M. Mari, F. Caballero, A. Colell et al., "Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis," *Cell Metabolism*, vol. 4, no. 3, pp. 185–198, 2006.
- [96] G. Musso, R. Gambino, and M. Cassader, "Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis," *Progress in Lipid Research*, vol. 52, no. 1, pp. 175–191, 2013.
- [97] T. Morita, "Heme oxygenase and atherosclerosis," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 9, pp. 1786–1795, 2005.
- [98] S. Petta, L. Miele, E. Bugianesi et al., "Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease," *PLoS ONE*, vol. 9, no. 2, Article ID e87523, 2014.
- [99] N. L. Beer, N. D. Tribble, L. J. McCulloch et al., "The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver," *Human Molecular Genetics*, vol. 18, no. 21, pp. 4081–4088, 2009.
- [100] N. Santoro, C. K. Zhang, H. Zhao et al., "Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents," *Hepatology*, vol. 55, no. 3, pp. 781–789, 2012.
- [101] L. Valenti, A. Alisi, and V. Nobili, "Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms," *Hepatology*, vol. 55, no. 3, pp. 661–663, 2012.
- [102] R. T. Acton, J. C. Barton, L. V. Passmore et al., "Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the hemochromatosis and iron overload screening (HEIRS) study," *Diabetes Care*, vol. 29, no. 9, pp. 2084–2089, 2006.
- [103] P. Dongiovanni, R. Rametta, A. L. Fracanzani et al., "Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study," *BMC Gastroenterology*, vol. 10, article 102, 2010.
- [104] P. Dongiovanni and L. Valenti, "Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility?" *PPAR Research*, vol. 2013, Article ID 452061, 8 pages, 2013.
- [105] R. Belfort, S. A. Harrison, K. Brown et al., "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis," *The New England Journal of Medicine*, vol. 355, no. 22, pp. 2297–2307, 2006.
- [106] J. H. Li, X. Q. Lao, H. L. Tillmann et al., "Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection," *Hepatology*, vol. 51, no. 6, pp. 1904–1911, 2010.
- [107] A. Tönjes, M. Scholz, M. Loeffler, and M. Stumvoll, "Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor  $\gamma$  with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals," *Diabetes Care*, vol. 29, no. 11, pp. 2489–2497, 2006.
- [108] M. Kumari, G. Schoiswohl, C. Chitraju et al., "Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase," *Cell Metabolism*, vol. 15, no. 5, pp. 691–702, 2012.
- [109] O. Olivieri, N. Martinelli, M. Sandri et al., "Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction," *Clinical Chemistry*, vol. 51, no. 2, pp. 360–367, 2005.
- [110] T. I. Pollin, C. M. Damcott, H. Shen et al., "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection," *Science*, vol. 322, no. 5908, pp. 1702–1705, 2008.
- [111] S. Gattu, E. M. Becker, and J. Y. M. Koo, "A rare case of non-Hodgkins B-cell lymphoma in a psoriatic patient: a case report and literature review," *Journal of Drugs in Dermatology*, vol. 9, no. 10, pp. 1277–1281, 2010.
- [112] D. Hirsch, A. Stahl, and H. F. Lodish, "A family of fatty acid transporters conserved from mycobacterium to man," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 15, pp. 8625–8629, 1998.
- [113] S. J. Steinberg, S. J. Mihalik, D. G. Kim, D. A. Cuebas, and P. A. Watkins, "The human liver-specific homolog of very long-chain acyl-CoA synthetase is cholate: CoA ligase," *The Journal of Biological Chemistry*, vol. 275, no. 21, pp. 15605–15608, 2000.
- [114] B. Hubbard, H. Doege, S. Punreddy et al., "Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity," *Gastroenterology*, vol. 130, no. 4, pp. 1259–1269, 2006.
- [115] H. Doege, D. Grimm, A. Falcon et al., "Silencing of hepatic fatty acid transporter protein 5 *in vivo* reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia," *The Journal of Biological Chemistry*, vol. 283, no. 32, pp. 22186–22192, 2008.
- [116] A. Auinger, L. Valenti, M. Pfeuffer et al., "A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis," *Hormone and Metabolic Research*, vol. 42, no. 12, pp. 854–859, 2010.
- [117] R. Fares, S. Petta, R. Lombardi et al., "The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis," *Liver International*, 2014.
- [118] A. E. Feldstein, N. W. Werneburg, A. Canbay et al., "Free fatty acids promote hepatic lipotoxicity by stimulating TNF- $\alpha$  expression via a lysosomal pathway," *Hepatology*, vol. 40, no. 1, pp. 185–194, 2004.

- [119] K. F. Petersen, S. Dufour, A. Hariri et al., "Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease," *New England Journal of Medicine*, vol. 362, no. 12, pp. 1082–1089, 2010.
- [120] J. Kozlitina, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs, "Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance," *Hepatology*, vol. 53, no. 2, pp. 467–474, 2011.
- [121] L. Valenti, V. Nobili, A. Al-Serri et al., "The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver," *Journal of Hepatology*, vol. 55, no. 6, pp. 1409–1414, 2011.
- [122] S. Petta, S. Grimaudo, C. Cammà et al., "IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease," *Journal of Hepatology*, vol. 56, no. 6, pp. 1356–1362, 2012.
- [123] F. Salomone, G. Li Volti, C. Rosso, G. Grosso, and E. Bugianesi, "Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis," *Journal of Gastroenterology and Hepatology*, vol. 28, no. 7, pp. 1202–1208, 2013.
- [124] P. Dongiovanni, A. L. Fracanzani, S. Fargion, and L. Valenti, "Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target," *Journal of Hepatology*, vol. 55, no. 4, pp. 920–932, 2011.